Elevated AST and ALT can sometimes signal heart disease, but the relationship runs in several directions and is more tangled than a simple yes-or-no answer allows. These two enzymes are best known as liver markers, yet AST in particular lives in heart muscle, skeletal muscle, and other tissues, so a spike does not automatically point to the liver at all. A heart attack, acute heart failure, or even chronic congestion from a weak heart can push both enzymes upward. At the same time, the metabolic conditions that damage the liver, such as fatty liver disease, overlap heavily with the risk factors for cardiovascular disease. Understanding which cardiac scenarios raise these enzymes, and which enzyme patterns hint at a cardiac rather than a hepatic problem, matters for anyone staring at an unexpected lab result.
How a Heart Attack Can Push Liver Enzymes Up
During a heart attack, dying heart muscle cells release their contents into the bloodstream. AST is abundant in cardiac tissue, so it surges quickly. In one study of patients with acute coronary syndromes, roughly 80 percent had elevated AST and about 47 percent had elevated ALT. Among those with large infarctions, approximately 93 percent showed AST concentrations more than three times the upper limit of normal.1PubMed Central. Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials? AST consistently runs higher than ALT after a heart attack, producing a characteristic pattern where the ratio of AST to ALT, called the De Ritis ratio, climbs well above 1. In patients with the most severe form of heart attack (STEMI), the average De Ritis ratio was about 3.2, compared with roughly 2.2 in patients with a less severe form (NSTEMI).2Termedia Publishing (Archives of Medical Science. Atherosclerotic Diseases). The significance of transaminase ratio (AST/ALT) in acute myocardial infarction – Section: Results
The practical takeaway here is that a very high De Ritis ratio in an acutely ill patient is not necessarily a liver problem. When AST shoots up far beyond ALT and the clinical picture includes chest pain, ECG changes, or troponin elevation, the heart is the likelier source. Clinicians have known this for decades, but outside the hospital, patients who see “elevated liver enzymes” on a report rarely think about their heart. The context of the elevation matters enormously.
Heart Failure and the Congested Liver
The liver sits downstream of the heart in the circulatory loop, so when the heart fails to pump effectively, the liver often takes collateral damage. This happens in two broad patterns depending on whether the problem is too little blood getting to the liver or too much blood backing up into it.
In acute heart failure or cardiogenic shock, blood pressure can drop so low that the liver essentially starves for oxygen. The result is sometimes called “shock liver” or ischemic hepatitis, and it can cause dramatic spikes in AST and ALT, occasionally into the thousands.3PubMed Central. Liver abnormalities in cardiac diseases and heart failure – Section: Abstract These numbers look alarming and can mimic acute viral hepatitis or a drug reaction, but they typically improve within days once circulation is restored. The key distinguishing feature is that shock liver tends to rise and fall fast, mirroring the hemodynamic crisis.
Chronic heart failure, by contrast, causes a slower, more insidious form of liver injury called congestive hepatopathy. When the right side of the heart is weak or the venous pressure stays high, blood pools in the hepatic veins and the liver becomes swollen and congested. Over months or years, this congestion leads to cellular injury, fibrosis, and impaired liver function.4PubMed Central. Congestive Hepatopathy: A Review of the Literature – Section: Abstract The transaminase elevations in congestive hepatopathy are usually milder than in shock liver, but they can persist, and the long-term risk of liver scarring is real. If you have heart failure and your doctor keeps an eye on your liver labs, this is why.
The AST-to-ALT Ratio as a Cardiac Prognostic Marker
The De Ritis ratio has taken on a second life in cardiology research as a tool for predicting outcomes, not just diagnosing what went wrong. Among patients with hypertension, every one-unit increase in the AST-to-ALT ratio was associated with a 32 percent higher risk of death from any cause in a fully adjusted model. The highest ratio group had nearly double the risk of cardiovascular death compared with the lowest group.5PubMed Central. The association between AST/ALT ratio and all-cause and cardiovascular mortality in patients with hypertension – Section: Results
A separate study of patients with confirmed coronary artery disease found that the prognostic value of a high De Ritis ratio depended on whether the individual enzymes were themselves abnormal. Among patients whose AST or ALT fell outside the normal range, those with a ratio above the median had about a 14 percent death rate over three years compared with roughly 7 percent for those below the median, with a statistically meaningful adjusted hazard ratio. But among patients whose enzymes were both in the healthy range, the ratio’s predictive power faded and was no longer statistically significant after adjustments.6PubMed Central. Association of De Ritis Ratio with Prognosis in Patients with Coronary Artery Disease and Aminotransferase Activity within and outside the Healthy Values of Reference Range – Section: RESULTS So a disproportionately high AST relative to ALT is worth paying attention to if the absolute values are also abnormal, but a slightly skewed ratio with normal numbers on both sides is less worrying.
When Low ALT Is the Problem
Most people worry about liver enzymes being too high. The less intuitive finding is that very low ALT can also spell trouble, particularly in people with existing heart disease. ALT is produced primarily by the liver, and its levels reflect, among other things, the amount of functional liver tissue and overall lean body mass. Very low levels tend to track with frailty, muscle wasting, and poor nutritional status.
In a long-term follow-up of middle-aged patients with stable coronary heart disease, those in the low ALT group had a cumulative all-cause mortality rate of about 66 percent over roughly 23 years, compared with about 58 percent for those with higher ALT. After adjusting for established risk factors, low ALT was independently associated with an 11 percent greater mortality risk.7PubMed Central. Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients – Section: Abstract A similar pattern appeared in patients with atrial fibrillation: those with the lowest ALT levels had significantly higher rates of both cardiovascular and all-cause death over a median follow-up of about three years.8Scientific Reports. Low alanine aminotransferase levels are independently associated with mortality risk in patients with atrial fibrillation – Section: Abstract
Research in older patients has added nuance. Low levels of both AST and ALT together were linked to frailty, sarcopenia, and disability, while high levels of both enzymes carried a different risk profile, including elevated cancer mortality.9PubMed Central. Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients – Section: Results The clinical implication is that a “perfectly normal” or even low ALT on a lab panel is not always reassuring in the setting of cardiovascular disease. It can be a quiet marker that the body is running low on reserves.
Fatty Liver Disease and Overlapping Cardiovascular Risk
One of the biggest reasons elevated transaminases and heart disease show up together is not that one causes the other directly, but that they share common soil. Metabolic-associated steatotic liver disease (formerly called nonalcoholic fatty liver disease, or NAFLD) is driven by insulin resistance, obesity, and dyslipidemia. These are the same metabolic forces that promote atherosclerosis. So a person with mildly elevated ALT from a fatty liver often carries the same risk profile as someone heading toward a cardiac event.
A large study found that fatty liver disease was significantly associated with coronary artery calcification, an early marker of atherosclerosis, alongside traditional risk factors like diabetes, high blood pressure, and smoking. Both AST and ALT were associated with the presence of calcium deposits in univariate analyses.10PubMed Central. Nonalcoholic Fatty Liver Disease is Associated with Coronary Artery Calcification – Section: Results However, whether the transaminases themselves are independent drivers of atherosclerosis or merely passengers along for the ride is less clear. A study of patients undergoing coronary angiography found that AST and ALT explained only a small fraction of the variance in coronary disease severity, concluding that the relationship “may be more complex than generally appreciated.”11PubMed Central. Atherosclerosis and Liver Function Tests in Coronary Angiography Patients – Section: Abstract
What this means for you: mildly elevated liver enzymes in the context of metabolic syndrome should prompt your doctor to think about cardiovascular risk, not just liver risk. But the enzymes themselves are more of a flag than a direct cause. They point to a metabolic environment that hurts both the liver and the arteries.
When Muscle Damage Mimics Liver Trouble
AST is not exclusive to the liver or the heart. Skeletal muscle contains plenty of it, which creates a common diagnostic trap. In rhabdomyolysis, where muscle tissue breaks down and dumps its contents into the blood, AST shoots up dramatically. One study found that about 93 percent of patients with significant rhabdomyolysis had an abnormal AST, while only 75 percent had an abnormal ALT. As muscle enzymes (measured by creatine phosphokinase, or CPK) fell during recovery, AST fell in parallel, while ALT did not track in the same way.12PubMed Central. Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury – Section: Abstract
This matters because rhabdomyolysis can sometimes cause cardiac complications of its own, including irregular heart rhythms from the potassium and other electrolytes released by dying muscle cells.13PubMed Central. Abnormal liver function tests associated with severe rhabdomyolysis – Section: Abstract A clinician seeing sky-high AST and a sick patient has to sort out whether the source is the liver, the heart, or the muscles. Checking CPK and troponin alongside the transaminases usually clarifies the picture, but when these tests are not done, the elevated AST can be misattributed. If you have recently had a severe injury, extreme exercise, or a seizure and your AST comes back dramatically elevated, muscle damage is a strong possibility regardless of how your heart or liver feels.
Heart Medications That Move the Numbers
Some of the drugs used to treat heart disease can themselves raise transaminases, creating confusion about whether the underlying cardiac condition or the treatment is driving the lab abnormality.
Statins, the most widely prescribed class of cardiovascular drugs, have long carried a reputation for liver harm. That reputation is largely outdated. In patients with fatty liver disease who also had cardiovascular disease, statin therapy was associated with a reduction, not an increase, in AST and ALT. One study found that ALT dropped from about 43 to about 36 U/L with statin treatment, with AST falling similarly. The statin group also showed less progression of liver fibrosis and fewer cardiovascular events.14PubMed Central. The Effect of Statin Therapy on Liver Enzymes and Fibrosis Progression in Patients With Coexisting Cardiovascular Disease and Non-alcoholic Fatty Liver Disease (NAFLD) – Section: Results A separate analysis confirmed that statin users with fatty liver disease actually had significantly lower ALT and were less likely to have elevated transaminases compared with non-users.15Journal of Clinical Lipidology. Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD) – Section: Results This is an area where the old fear of statin-induced liver injury has been replaced by evidence suggesting statins may actually help the liver in people with metabolic disease.
Amiodarone, a powerful anti-arrhythmic medication, tells a different story. When given intravenously, it can cause acute hepatocellular injury, sometimes with dramatic transaminase spikes. The mechanism involves multiple factors including the solvent used in the IV formulation, which may trigger mitochondrial dysfunction and reduced blood flow to the liver.16European Journal of Cardiovascular Medicine. Intravenous Amiodarone – Induced Acute Liver Injury: Early Recognition and Management with N-Acetylcysteine – Section: Abstract This type of injury is usually reversible once the drug is stopped, but it requires quick recognition. Anticoagulants, certain antihypertensives, and other cardiac drugs can also nudge transaminases upward in some patients. The point is that an elevated lab value in someone on cardiac medications does not necessarily mean the heart disease is worsening; the treatment itself could be the explanation.
Alcohol, the Heart, and the Liver Together
Heavy alcohol use damages both the liver and the heart, and the transaminase pattern can reflect the severity of liver disease rather than simply how much someone has been drinking. A study of patients at different stages of alcoholic liver disease found that the AST-to-ALT ratio rose progressively with disease severity. Among those with only mild liver changes, about 64 percent had a ratio at or below 1.0. But among those with cirrhosis, 69 percent had a ratio of 2.0 or higher.17PubMed. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking
This overlap matters because alcoholic cardiomyopathy, where chronic drinking weakens and enlarges the heart, often coexists with alcoholic liver disease. A patient with both conditions can present with elevated transaminases that reflect liver fibrosis, cardiac congestion compounding the liver damage, and possibly direct cardiac injury all at once. Disentangling the contributions is genuinely difficult, and the De Ritis ratio in this context carries a different meaning than in a patient having a heart attack. A high ratio here more likely signals advanced liver scarring rather than acute cardiac muscle death. Context, as always, is everything.
Congenital Heart Disease and Long-Term Liver Effects
Not all cardiac causes of transaminase elevation are acquired. Patients born with certain complex heart defects, particularly those who have undergone the Fontan procedure to reroute blood flow, live with chronically elevated venous pressure for life. This sustained pressure on the liver produces a distinctive form of congestive hepatopathy called Fontan-associated liver disease. The condition is driven by high, non-pulsatile central venous pressure and reduced cardiac output, both built into the way Fontan circulation works.18PubMed Central. Fontan-associated liver disease: Diagnosis, surveillance, and management – Section: Abstract
Fontan-associated liver disease develops in virtually all patients over time, and transaminase elevations are just one part of a broader picture that can include liver fibrosis, cirrhosis, and even liver cancer. These patients require lifelong liver surveillance alongside cardiac care. It is a stark example of how the heart and liver are not separate organ systems that happen to share a body; they are hemodynamically linked, and what happens to one inevitably affects the other.
Sex Differences in Liver Enzyme Thresholds
Standard lab reference ranges for AST and ALT differ between men and women, but the metabolic underpinnings of these enzymes also behave differently between sexes. Research has shown that the association between liver enzymes (including ALT, AST, and GGT) and fatty liver disease varies significantly by sex.19PubMed Central. Gender perspective on the association between liver enzyme markers and non-alcoholic fatty liver disease: insights from the general population – Section: Results Since fatty liver disease is itself a cardiovascular risk factor, these sex-specific differences in enzyme behavior have downstream implications for how we interpret cardiac risk from a routine blood panel.
Women generally have lower normal values for both AST and ALT, which means a level that looks “normal” by a lab’s printed range might actually be abnormally high for a given woman. Some researchers have argued that current upper limits of normal for ALT are set too high, particularly in women, and that lowering them would catch more metabolic disease earlier. For anyone assessing cardiac risk through the lens of liver enzymes, applying the same cutoffs to men and women can miss meaningful elevations.
Do Time of Day or Lifestyle Factors Affect These Numbers
One concern patients sometimes raise is whether the timing of a blood draw, a recent workout, or a large meal the night before could produce a misleadingly high result. A population-level study found that clinically significant diurnal variation in ALT was essentially absent. Among women, afternoon ALT was barely half a unit higher than morning values, a difference so small it would not change any clinical interpretation. Among men and adolescents, no meaningful difference was found.20PubMed Central. Diurnal Variation in Serum Alanine Aminotransferase Activity in the United States Population – Section: RESULTS So time of day is not a factor you need to worry about.
Intense exercise, however, is a genuine confounder. A hard gym session or endurance event can elevate AST by releasing it from stressed muscle fibers, mimicking the pattern described earlier in rhabdomyolysis, just at a milder scale. Acute alcohol consumption, certain supplements, and some herbal products can also transiently raise transaminases. If your results come back mildly elevated and you had an unusually intense workout in the day or two before the blood draw, a repeat test under rested conditions is a reasonable step before assuming something is wrong with your liver or heart.